CBC Stats & Data

CBC is a rare, non-intoxicating cannabinoid present at low levels in Cannabis sativa. In vitro work shows CBC acts as a potent agonist at TRPA1 channels and can desensitize TRP channels, which aligns with analgesic and anti-inflammatory signals in preclinical models; however, TRPA1 activation is also linked to burning/irritant sensations in humans, so inhalation can cause throat or airway irritation in sensitive users. Human pharmacology data remain sparse; most information comes from animal experiments and user reports from CBC isolates (tinctures, vape cartridges). Because several phytocannabinoids (e.g., THC, CBD, CBN) inhibit major drug‑metabolizing CYP enzymes in vitro (notably 2C9, 2C19, 2D6, 3A4), and specific CBC interaction data are limited, medications with a narrow therapeutic index metabolized by these enzymes (such as warfarin for CYP2C9) warrant extra caution and monitoring. Avoid vape products containing vitamin E acetate or other oil diluents not intended for inhalation; vitamin E acetate has been identified by European early warning systems as a high‑concern substance when inhaled. For oral use, high‑fat meals can markedly increase cannabinoid exposure (demonstrated for CBD), so keep meal patterns consistent to avoid unintended dose escalation. High‑dose CBD can elevate liver enzymes; while this has not been demonstrated for CBC, prudence suggests caution with pre‑existing liver disease or when combining multiple cannabinoids over long periods. Until individual response is known, avoid driving or operating machinery after dosing, and avoid combining with other CNS depressants. Prefer regulated or lab‑tested products and, where available, consider drug checking services to reduce contamination risks. Storage away from heat and light is advisable as cannabinoids can degrade under harsh conditions, although human‑relevant CBC degradation pathways are not well characterized.